Figure 8 shows that the ABCA−B/−B-T2DM stroke mice exhibit an increased level of protein and mRNA of ED-1, MCP-1, and TLR-4, whereas a lower level of IGF-1/IGF-1Rβ in the ischemic brain tissues when compared that with the ABCA1fl/fl-T2DM stroke mice at 21 days after dMCAo (p < 0.05, n = 6/group). L-4F treatment significantly decreases ED-1, MCP-1, and TLR-4 expression and increases IGF-1 and IGF-1Rβ levels in the ischemic brain compared with the vehicle-control group, respectively (p < 0.05, n = 6/group). This evidence concerns the gene CCL2 and stroke disorder.